Evaluation of a new generation synthetic peptide combination assay for detection of antibodies to HIV-1, HIV-2, HTLV-I, and HTLV-II simultaneously

✍ Scribed by Xiang Zhang; Dr. Niel T. Constantine; Jaya Bansal; Johnny D. Callahan; Vincent C. Marsiglia

• Publisher: John Wiley and Sons
• Year: 1992
• Tongue: English
• Weight: 538 KB
• Volume: 38
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890380111

✦ Synopsis

Abstract

A new generation combination test (Detect‐Plus, IAF BioChem, Montreal, Canada) based on synthetic peptides for HIV‐1, HIV‐2, HTLV‐I, and HTLV‐II was compared with three routine commercial screening assays and confirmatory assays to determine its sensitivity and specificity and to evaluate it as a substitute screening method. Samples from 356 sexually transmitted disease (STD) patients were tested by the four screening tests. All initially reactive samples were retested in duplicate by the corresponding EIA and repeatedly reactive samples were confirmed by Western blots for HIV‐1, HIV‐2, and HTLV‐1/11. The confirmed positives detected by each screening assay were HIV‐1 (23/356,6.46%), HIV‐2 (1 1/356,3.09%), and HTLV‐1/11 (5/356,1.4%). The new generation Detect‐Plus test produced only two results (2/356, 0.56%) that were presumed t o be false‐positives in comparison to the screening tests, but the OD/CO values were just slightly high (1.5 and 1.9). There were no false negative results, indicating that the sensitivity of the new combination test was excellent (100%). Compared with routine retroviral EIA assays, the test is easy to perform—the total time requirement is only 2 hr and there is no need for incubation equipment. The OD/CO values were very high when samples were positive, making even visual interpretation possible. We conclude that this new combination assay is an excellent screening method for detection of antibodies to the human retroviruses, and may be particularly useful for screening blood for transfusion and in epidemiological investigations. © 1992 Wiley‐Liss, Inc.